Literature DB >> 5549923

Clinical and metabolic studies with imipramine in man.

P Zeidenberg, J M Perel, M Kanzler, R N Wharton, S Malitz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 5549923     DOI： 10.1176/ajp.127.10.1321

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN： 0002-953X            Impact factor:   18.112


× No keyword cloud information.
  6 in total

Review 1.  Clinically Significant Drug-Drug Interactions with Agents for Attention-Deficit/Hyperactivity Disorder.

Authors:  Georgios Schoretsanitis; Jose de Leon; Chin B Eap; John M Kane; Michael Paulzen
Journal:  CNS Drugs       Date:  2019-12       Impact factor: 5.749

Review 2.  Clinical use of psychotherapeutic drugs. II. Antidepressant and antianxiety drugs and special problems in the use of psychotherapeutic drugs.

Authors:  L E Hollister
Journal:  Drugs       Date:  1972       Impact factor: 9.546

3.  Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trials.

Authors:  Ivelina Gueorguieva; Kimberley Jackson; Steven A Wrighton; Vikram P Sinha; Jenny Y Chien
Journal:  Br J Clin Pharmacol       Date:  2010-10       Impact factor: 4.335

Review 4.  Clinical pharmacokinetics of imipramine and desipramine.

Authors:  F R Sallee; B G Pollock
Journal:  Clin Pharmacokinet       Date:  1990-05       Impact factor: 6.447

Review 5.  Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder.

Authors:  J S Markowitz; K S Patrick
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 6.  Pharmacokinetic optimisation of therapy with newer antidepressants.

Authors:  P J Goodnick
Journal:  Clin Pharmacokinet       Date:  1994-10       Impact factor: 6.447
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.